Objectives The Gynecologic Cancer InterGroup aimed to provide an overview of uterine and ovarian leiomyosarcoma management.
Methods Published articles and author experience were used to draft management overview. The draft manuscript was circulated to international members of the Gynecologic Cancer InterGroup for review and comment, and appropriate revisions were made.
Results The approach to management of uterine and ovarian leiomyosarcoma management is reviewed.
Conclusions Uterine and ovarian leiomyosarcomas are rare and aggressive cancers that require specialized expertise for optimal management.
- Uterine leiomyosarcoma
- Ovarian leiomyosarcoma
- Gynecologic Cancer InterGroup
Statistics from Altmetric.com
Financial disclosures: AL Hamilton served on the advisory board for GlaxoSmithKline. J. Maenpaa received grant funding and payment for lectures from Roche Finland, serves on the board for Roche Finland and MSD Finland, has acted as a consultant for Amgen Nordic and Janssen Cilag Finland, and has received meeting expense funding from LeoPharma, Janssen, and Sandoz. P. Pautier served on the advisory board of Pharmamar Laboratory.
The remaining authors declare no conflicts of interest.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.